Healthcare / BiotechnologyNZSE
$0.02
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 20%
FCF escenarios
weak_data · normalized FCF $486000.00 · quality 52.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
52/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$22M
P/E
24.3x
↑EV/EBITDA
8.5x
↓ROE
6.8%
↑Gross Margin
77.9%
↑Debt/Equity
0.05
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+9.5%
FCF CAGR
—
FCF margin
11.3%
FCF / Net income
1.56x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $11.6M · net income $838000.0 · FCF $1.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $11.6M | $11.6M | $10.5M | $10.0M | $8.8M |
| Net Income | $838000.00 | $838000.00 | $646000.00 | $-1.4M | $-2.7M |
| EBITDA | $1.5M | $1.5M | $1.3M | $-746000.00 | $-2.0M |
| EPS | 0.00 | 0.00 | 0.00 | -0.00 | -0.00 |
| Gross Margin | 77.9% | 77.9% | 78.5% | 78.0% | 78.1% |
| Operating Margin | -10.2% | -10.2% | -12.3% | -24.3% | -45.0% |
| Net Margin | 7.2% | 7.2% | 6.2% | -13.6% | -30.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.05 | 0.05 | 0.03 | 0.06 | 0.06 |
| Current Ratio | 7.56 | 7.56 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.3M | $1.3M | $486000.00 | $9000.00 | $-2.6M |
| Returns | |||||
| ROE | 6.8% | 6.8% | 5.6% | -12.5% | -22.3% |
| Valuation | |||||
| P/E | 24.29 | 24.29 | 32.00 | — | — |
| EV/EBITDA | 8.53 | 8.53 | 9.76 | — | — |
| P/B | 1.76 | 1.76 | 1.77 | 3.29 | 4.15 |
| Growth & Yield | |||||
| Revenue Growth | 10.3% | 10.3% | 5.4% | 13.1% | — |
| EPS Growth | 40.0% | 40.0% | 145.5% | 50.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
29.2%
EPS terminal req.
$0.00
Spread vs growth
10.8%
5Y implied EPS CAGR
21.1%
EPS terminal req.
$0.00
Spread vs growth
18.9%
10Y implied EPS CAGR
15.4%
EPS terminal req.
$0.00
Spread vs growth
24.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+0.0%
Start / end P/E
34.0x → 24.3x
EPS bridge
0.00 → 0.00
Residual
-11.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.